Feb. 24 at 9:03 PM
$POET Part 4) The "Poison Pill" & Buyout Math
POET’s recent
$150M raise at
$7.25 acts as a "functional poison pill." By amassing a ~
$300M war chest, the board removed the "distress" factor, forcing any suitor like Marvell to pay a premium rather than waiting for a cash crunch. The
$7.25 floor sets the stage for high-valuation M&A. Speculative buyout targets currently range from
$3B to
$4B, which translates to approximately
$15–
$25 per share. The primary trigger for a deal is expected in late 2026, once POET demonstrates 90%+ manufacturing yields at its Malaysia facility, proving the tech is ready for global mass-market deployment.
